Want to see IN:APLLTD full AI Analyst Report?
APLLTD Stock Chart & Stats
₹930.30
-₹4.90(-0.46%)
At close: 4:00 PM EST
₹930.30
-₹4.90(-0.46%)
Day’s Range― - ―
52-Week Range₹635.30 - ₹1,064.70
Previous CloseN/A
Volume60.71K
Average Volume (3M)9.71K
Market Cap
₹162.23B
Enterprise Value₹142.31K
Total Cash (Recent Filing)₹2.03B
Total Debt (Recent Filing)₹14.30B
Price to Earnings (P/E)24.0
Beta1.06
Next Earnings
Jul 31, 2026EPS Estimate
7.79Next Dividend Ex-DateN/A
Dividend Yield1.28%
Share Statistics
EPS (TTM)34.32
Shares Outstanding196,563,130
10 Day Avg. Volume3,953
30 Day Avg. Volume9,706
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)2.30
Price to Sales (P/S)1.77
P/FCF Ratio50.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)37.74
Revenue Forecast (FY)₹81.87B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent top-line growth (~10% recent) indicates durable demand for its branded generics and international generics. Over 2-6 months this supports scale benefits in manufacturing, sales reach and pipeline commercialization, making future launches and investment less binary.
Conservative Balance SheetLow leverage and expanding shareholders' equity provide financial flexibility for sustained capex, product registrations and working-capital needs. This conservatism reduces refinancing risk, enabling long-term R&D and manufacturing investments through business cycles.
Integrated Formulations + API CapabilitiesVertical capabilities across APIs and finished dosages plus exposure to multiple therapeutic areas and geographies enhance resilience. Integration supports margin control, supply reliability and faster commercialization — a structural advantage versus pure-play manufacturers.
Bears Say
Volatile Cash GenerationLarge year-to-year swings in operating and free cash flow signal execution and working-capital variability. This undermines predictable reinvestment and dividend capacity, complicates multi-quarter planning for launches and may force opportunistic financing in weaker periods.
Margin Compression Vs PeakMargins have contracted from earlier peaks, reflecting pricing pressure or cost changes. Sustained margin compression would reduce earnings power and free cash conversion, limiting long-term ability to fund growth or absorb competitive shocks without operational improvements.
Reliance On US Approvals & Competitive LaunchesSignificant exposure to the US generic market makes future revenue contingent on regulatory approvals and contested launches. Structural competitive intensity and pricing erosion in that market can produce durable volatility in revenues and delay payback on development costs.
Alembic Pharmaceuticals Limited News
APLLTD FAQ
What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?
Alembic Pharmaceuticals Limited lowest stock price was ₹635.30 and its highest was ₹1064.70 in the past 12 months.
What is Alembic Pharmaceuticals Limited’s market cap?
Alembic Pharmaceuticals Limited’s market cap is ₹162.23B.
When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?
Alembic Pharmaceuticals Limited’s upcoming earnings report date is Jul 31, 2026 which is in 12 days.
How were Alembic Pharmaceuticals Limited’s earnings last quarter?
Alembic Pharmaceuticals Limited released its earnings results on May 15, 2026. The company reported ₹11.5 earnings per share for the quarter, beating the consensus estimate of ₹8.655 by ₹2.845.
Is Alembic Pharmaceuticals Limited overvalued?
According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued.
Does Alembic Pharmaceuticals Limited pay dividends?
Alembic Pharmaceuticals Limited pays a Annually dividend of ₹12 which represents an annual dividend yield of 1.28%. See more information on Alembic Pharmaceuticals Limited dividends here
What is Alembic Pharmaceuticals Limited’s EPS estimate?
Alembic Pharmaceuticals Limited’s EPS estimate is 7.79.
How many shares outstanding does Alembic Pharmaceuticals Limited have?
Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.
What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?
Alembic Pharmaceuticals Limited reported an EPS of ₹11.5 in its last earnings report, beating expectations of ₹8.655. Following the earnings report the stock price went down -0.223%.
Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:APLLTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a wide array of formulations. The company provides both proprietary (branded) and generic medications, addressing numerous therapeutic needs such as cardiovascular health, women's health, gastrointestinal issues, eye and skin conditions, kidney/urinary tract disorders, orthopedic ailments, anti-infective treatments, remedies for cold and cough, and anti-diabetic management. Furthermore, the company engages in the export of its diverse product portfolio. Founded in 1907, Alembic Pharmaceuticals Limited maintains its main office in Vadodara, India.
Technical Analysis
Glenmark Life Sciences Limited
―
Granules India Limited
―
Jubilant Pharmova Limited
―
NATCO Pharma Limited
―
Piramal Pharma Limited
―